Related references
Note: Only part of the references are listed.Modification of the primary tumor microenvironment by transforming growth factor α-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model
Takamitsu Sasaki et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer
H. J. Burstein et al.
ANNALS OF ONCOLOGY (2008)
Emerging roles of ADAM and ADAMTS metalloproteinases in cancer
N. Rocks et al.
BIOCHIMIE (2008)
Survival of cancer cells is maintained by EGFR independent of its kinase activity
Zhang Weihua et al.
CANCER CELL (2008)
Equilibrium between host and cancer caused by effector T cells killing tumor stroma
Bin Zhang et al.
CANCER RESEARCH (2008)
Membrane-anchored growth factors, the epidermal growth factor family: Beyond receptor ligands
Shigeki Higashiyama et al.
CANCER SCIENCE (2008)
c-Src trafficking and co-localization with the EGF receptor promotes EGF ligand-independent EGF receptor activation and signaling
Mrudula Donepudi et al.
CELLULAR SIGNALLING (2008)
Polarized immune responses differentially regulate cancer development
Magnus Johansson et al.
IMMUNOLOGICAL REVIEWS (2008)
IFN-γ- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers
Bin Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The epidermal growth factor receptor system in skin repair and inflammation
Saveria Pastore et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer
David F. Stern
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2008)
CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone
Sreenivasa R. Chinni et al.
MOLECULAR CANCER RESEARCH (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Molecular origins of cancer: Oncogenes and cancer
Carlo M. Croce
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Molecular origins of cancer - Cancer immunology
Olivera J. Finn
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion
P. Arora et al.
ONCOGENE (2008)
Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations
C. Q. Cai et al.
ONCOGENE (2008)
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
D. L. Wheeler et al.
ONCOGENE (2008)
Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes
Z. Cai et al.
ONCOGENE (2008)
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Daniel Tracey et al.
PHARMACOLOGY & THERAPEUTICS (2008)
Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors
Toshio Kuwai et al.
NEOPLASIA (2008)
Ligand release-independent transactivation of epidermal growth factor receptor by transforming growth factor-β involves multiple signaling pathways
C-K Joo et al.
ONCOGENE (2008)
17 beta-estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment
Alessandra Pattarozzi et al.
MOLECULAR PHARMACOLOGY (2008)
The role of the EGFR signaling in tumor microenvironment
Antonella De Luca et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2008)
ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis
F. Revillion et al.
ANNALS OF ONCOLOGY (2008)
Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2
Stefania Varchetta et al.
CANCER RESEARCH (2007)
Mitogenic signaling pathways induced by G protein-coupled receptors
Enrique Rozengurt
JOURNAL OF CELLULAR PHYSIOLOGY (2007)
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
Sizhi Paul Gao et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non-small cell lung cancer
Roy S. Herbst et al.
CLINICAL CANCER RESEARCH (2007)
Display, engineering, and applications of antigen-specific T cell receptors
Sarah A. Richman et al.
BIOMOLECULAR ENGINEERING (2007)
Mapping ErbB receptors on breast cancer cell membranes during signal transduction
Shujie Yang et al.
JOURNAL OF CELL SCIENCE (2007)
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB Ligands and remain dependent on the ErbB receptor network
Christoph A. Ritter et al.
CLINICAL CANCER RESEARCH (2007)
ErbB receptors: from oncogenes to targeted cancer therapies
Hongtao Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Tumor immunoediting and immunosculpting pathways to cancer progression
Jennifer M. Reiman et al.
SEMINARS IN CANCER BIOLOGY (2007)
Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: Correlation with clinical outcome
Anastassios V. Koutsopoulos et al.
LUNG CANCER (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy
Grazia Arpino et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
HER-2/neu raises SHP-2, stops IFN-γ anti-proliferation in bladder cancer
Wen-Pin Su et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Sensitization of TNF-induced cytotoxicity in lung cancer cells by concurrent suppression of the NF-κB and Akt pathways
Xia Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
TheEGF receptor family: spearheading a merger of signaling and therapeutics
Erez M. Bublil et al.
CURRENT OPINION IN CELL BIOLOGY (2007)
Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation
F. Luppi et al.
LUNG CANCER (2007)
Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer
Jordan S. Fridman et al.
CLINICAL CANCER RESEARCH (2007)
Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
Alison Reid et al.
EUROPEAN JOURNAL OF CANCER (2007)
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia V. Sergina et al.
NATURE (2007)
Extracellular heat shock protein 70 mediates heat stress-induced epidermal growth factor receptor transactivation in A431 carcinoma cells
Anton L. Evdonin et al.
FEBS LETTERS (2006)
HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy
X-F Wen et al.
ONCOGENE (2006)
Epidermal growth factor receptor targeting in cancer
John Mendelsohn et al.
SEMINARS IN ONCOLOGY (2006)
ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors
Haruhiko Ohtsu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2006)
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab
CW Adams et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: Implications for progression of ErbB2-overexpressing tumors
Lixing Zhan et al.
CANCER RESEARCH (2006)
ErbB-receptors expression and survival in breast carcinoma: A 15-year follow-up study
S Bianchi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
Recent advances in MMP inhibitor design
JF Fisher et al.
CANCER AND METASTASIS REVIEWS (2006)
Development of a novel strategy for engineering high-affinity proteins by yeast display
S. A. Richman et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2006)
TGF-α and ErbB2 production in synovial joint tissue:: increased expression in arthritic joints
AL Hallbeck et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2005)
Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival
SM Wiseman et al.
CANCER (2005)
The ErbB receptors and their ligands in cancer: An overview
N Normanno et al.
CURRENT DRUG TARGETS (2005)
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy
LM Friedman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells
CA Wilson et al.
BREAST CANCER RESEARCH (2005)
Induced autocrine signaling through the epidermal growth factor receptor contributes to the response of mammary epithelial cells to tumor necrosis factor α
WNU Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity
J Lustgarten et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
A role for Janus kinases in crosstalk between ErbB3 and the interferon-alpha signaling complex in myeloma cells
DK Walters et al.
ONCOGENE (2004)
Epidermal growth factor receptor transactivation mediates tumor necrosis factor-induced hepatocyte replication
GM Argast et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer
A Onn et al.
CLINICAL CANCER RESEARCH (2004)
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis
YM Li et al.
CANCER CELL (2004)
Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors
G Hudelist et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family
MU Martin et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2002)
Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association
E Penuel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The ErbB receptor tyrosine family as signal integrators
NE Hynes et al.
ENDOCRINE-RELATED CANCER (2001)
Identification of new epitopes from four different tumor-associated antigens: Recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity
E Keogh et al.
JOURNAL OF IMMUNOLOGY (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-κB pathway
BP Zhou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Tyrosine kinase signalling in breast cancer - Epidermal growth factor receptor: convergence point for signal integration and diversification
N Prenzel et al.
BREAST CANCER RESEARCH (2000)